Odyssey Announces Agreement to Combine with BenevolentAI
London and Amsterdam (ots/PRNewswire) - - BenevolentAI is a leading, clinical-stage AI drug discovery company that combines advanced AI and machine learning with cutting edge science to discover and develop novel and more effective medicines - Combination of BenevolentAI with Odyssey, a EUR300m Euronext Amsterdam-listed special purpose acquisition company focused on European healthcare and technology, represents the ...
mehr